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MIXL1, an evolutionarily conserved, paired-type homeobox transcription
factor induced by BMP4/TGFb signaling, is a critical regulator of embryonic and
adult hematopoiesis. Several lines of evidence implicate MIXL1 in hematopoietic
transformation: (i) Aberrant MIXL1 expression is seen in human CML ( Chronic
Myelogenous Leukemia) in blast crisis, AML (Acute myelogenous leukemia), B
cell lymphomas and pediatric ALL (Acute lymphocytic leukemia). (ii) Retroviral
transduction of Mixl1 induces AML in murine models. Nonetheless, mechanisms
underlying MIXL1 mediated proliferative, survival advantages are unknown.
The goal of my studies is to understand if and how aberrant MIXL1
expression contributes to leukemogenesis. As a first step, I sought to determine
transcriptional targets of MIXL1. Using MIXL1 overexpression lines established
in the human myelomonocytic leukemia cell line, U937, I performed global
chromatin immunoprecipitation coupled sequencing (ChIP-Seq), expression
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profiling studies I identified several putative targets. Of these, the proto-oncogene
c-REL was an important target. Both ectopically expressed and endogenous
MIXL1 bound REL promoters in myelogenous leukemia cells.

Furthermore,

cREL was induced under MIXL1 over-expression conditions in the leukemic cell
line U937. Targeted shRNA mediated knockdown of endogenous MIXL1 in AML
cell lines down regulated REL expression.
c-REL the cellular homolog of the viral oncogene v-rel encoded by the
oncogenic reticuloendotheliosis retrovirus, is a member of the Nf-κB/Rel gene
family. c-REL transcriptionally activates proliferation and immune response and
represses apoptosis through upregulation of anti-apoptotic genes. c-REL plays a
critical role in hematopoietic differentiation. It is required for B-cell differentiation,
and dendritic cells to activate T cells. In the myeloid lineage, c-REL is critical for
macrophage mediated innate immunity. My findings suggest that transcriptional
up regulation of REL by MIXL1, therefore would promote survival or proliferation
through activation of the Nf-κB pathway in AML cells. Consistent with these
established activities of c-REL, expression of two anti-apoptotic genes BCL2A1
and BCL2L1 increased under MIXL1 over-expression conditions and decreased
under conditions of MIXL1 knockdown by targeted shRNA in U937 cells.

In

summary, my studies identify c-REL to be a novel mediator of MIXL1-induced
survival signals in leukemia.
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Activin A – A cytokine belonging to the TGF-β superfamily.
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ALK3 (BMPR1A) – Bone Morphogenic Protein receptor, type 1A, a BMP-type
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ALK6 (BMPR1B) – Bone Morphogenic Protein receptor, type 1B, a BMP-type
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AVCR2A – Activin type 2 receptor A, a BMP-type member of the TGF-β receptor
superfamily. Can be activated by Activin and BMP.
ALX4 – ALX Homeobox 4, a paired-type homeobox transcription factor.
APBB2 – Amyloid beta A4 precursor protein-binding family B member 2.
BCL2 – B-cell lymphoma 2, an anti-apoptotic gene that regulates chytochrome-c
mediated apoptosis.
BCL2A1 – BCL2-related protein A1, a BCL2 family member and an antiapoptotic gene that regulates chytochrome-c mediated apoptosis.
BCL2L1 – BCL2-like protein 1, a BCL2 family member and an anti-apoptotic
gene that regulates chytochrome-c mediated apoptosis.
BMP4 – Bone Morphogenic Protein 4, a cytokine belonging to the TGF-β
superfamily.
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BMPR1 – Bone Morphogenic Protein receptor, type 2, a BMP-type member of
the TGF-β receptor superfamily. Can be activated by BMP proteins.
BRCA1– Breast Cancer 1, early onset, a RING zinc finger protein.
CAMKK2 – Calcium/calmodulin-dependent protein kinase kinase 2, a

calmodulin-dependant serine/threonine kinase.
CDX2 – Caudal type homeobox 2, a caudal-related homeobox transcription
factor.
DLX1 –Distal-less homeobox 1, a homeobox transcription factor with similarity to
the Drosphilia distal-less gene.
DLX4 –Distal-less homeobox 4, a homeobox transcription factor with similarity to
the Drosphilia distal-less gene.
EGR1 – Early growth response 1, a C2H2-type zinc-finger transcription factor.
EIF1 – Eukaryotic translation initiation factor 1.
EOMES – Eukaryotic translation initiation factor 1.
GSC – Goosecoid homeobox, a paired-type homeobox transcription factor.
HHEX– Hematopoietically-expressed homeobox, a homeobox transcription
factor.
HLX – H2.0-like homeobox, a homeobox transcription factor.
HOXA9 –Homeobox A9, a homeobox transcription factor of the cluster A
subgroup.
IL18R1 –Interleukin 18 receptor 1, an Interleukin cytokine receptor, that
specifically binds to interleukin 18.
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MIXL1 –Mesoderm inducer in Xenopus like 1, a paired type homeobox
transcription factor.
MZF1 – Myeloid zinc finger 1, a C2H2-type zinc finger transcription factor.
NEUROD1 – Neuronal differentiation 1, a helix-loop-helix transcription factor.
NF-κB – A ubiquitous transcription factor protein dimer that consists of either NFκB1/p50 or NF-κB2/p49 in complex with REL, RELA, or RELB. The most
prevalent form is NF-κB1/p50 in complex with RELA.
NFKB1 –Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, a
NF-κB/REL-family transcription factor that produces the protein NF-κB1/p50, part
of the most prevalent “canonical” NF-κB protein dimer alongside RELA.
NFKB2 – Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, a
NF-κB/REL-family transcription factor that produces the protein NF-κB2/p49.
NFKBIA,B,E – Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha, beta, and epsilon, a family of proteins that bind to NF-κB/REL
dimers to inhibit their function.
NKX2-1 – NK2 homeobox 1, a homeobox transcription factor.
OTX2 – orthodenticle homeobox 2, a paired-type homeobox transcription factor.
PCGF2 – Polycomb group RING finger protein 2, a RING finger containing
protein.
PML–Promyelocytic leukemia protein, is a homeobox transcription factor.
POU4F2 –POU class 4 homeobox 2, is a homeobox transcription factor.

xiii

c-REL – v-rel avian reticuloendotheliosis viral oncogene, a NF-κB/REL-family
transcription factor and family member that shares the most sequence homolog
to the viral oncogene.
RELA – v-rel avian reticuloendotheliosis viral oncogene homolog A (p65), a NFκB/REL-family transcription factor and part of the most prevalent “canonical” NFκB protein dimer alongside NF-κB1/p50.
RELB – v-rel avian reticuloendotheliosis viral oncogene homolog B, a NFκB/REL-family transcription factor.
RUNX1 – RUNT related transcription factor 1, a transcription factor that regulates
hematopoietic stem cell differentiation.
SLC39A13 – Solute carrier family 39 (zinc transporter), member 13, a
transmembrane zinc transporter.
SMAD – A family of signal transduction proteins that transcriptionally regulate
targeted genes in response to TGF-β family signaling pathways.
SMYD5 – SMYD family member 5, a methyltransferase.
Sp1 – Sp1 transcription factor, a SP/KLF family zinc finger transcription factor.
T – A gene that encodes the T box transcription factor Brachyury.
TBX6 – T-box 6, a T box transcription factor.
TBX20 – T-box 20, a T box transcription factor.
TGF-β – Transforming growth factor beta, a family of cytokines that regulate
proliferation, differentiation, migration, and other pathways through interaction
with TGF-β receptors. Part of the same superfamily of cytokines as BMP and
Activin.
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VEG-FR – Vascular endothelial growth factor Receptor, a family of receptors that
interact with VEGF, and are important for vasculogenesis and angiogenesis.
YES1 – v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1, src family
tyrosine kinase and homolog to the Yamaguchi sarcoma virus oncogene.
ZP3 – Zona pellucida glycoprotein 3 (sperm receptor), an extracelular matrix
protein.
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ABBREVIATIONS – Other
6-FAM – 6-Carboxyfluorescein, a common fluorescent dye used for attachment
to oligonucleotides, especially in real time PCR techniques.
ALL – Acute lymphoblastic leukemia.
AML – Acute myelogenous leukemia.
ChIP – Chromatin Immunoprecipitation, A technique for identification of in vitro or
in vivo interactions between proteins and chromosomal DNA by DNA/protein
crosslinking, immunoprecipitation and then DNA extraction.
ChIP-qPCR – ChIP-coupled qPCR, a technique for quantifying and evaluating
the prevalence of a DNA/protein interaction by using quantitative PCR against
desired targets on DNA samples produced by ChIP.
ChIP-Seq – ChIP-coupled sequencing, a high throughput technique for
identifying, quantifying, and evaluating the prevalence of DNA/protein
interactions by using high-throughput sequencings techinues on DNA samples
produced by ChIP.
CML – Chronic myelogenous leukemia.
Ct (qPCR) – Cycle Threshold, a raw data value representing the prevalence of
nucleic acid sequencing in a quantitative PCR reaction. The Ct value is the cycle
of PCR reaction where the fluorescence signal passed a set threshold, so lower
Ct values mean higher abundance of DNA sequence.
DMSO – Dimethyl sulfoxide.
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Dorsomorphin –Dorsomorphin dihydrochloride, a serine/threonine kinase
inhibitor which can potently inhibit for BMP/Acitivin related receptor kinases and
AMP-activated protein kinase (AMPK).
Doxorubicin – A cancer chemotherapy commonly used for leukemia and other
cancers. It functions by intercalating DNA, blocking DNA replication.
ECL Reagent – Enhanced chemiluminescence reagent, a luminol-based
detection reagent used for western blotting.
FLAG – A polypeptide epitope tag. Amino Acid Sequence: DYKDDDDK
Fibrodysplasia ossificans progressiva – A rare chronic disease that causes
fibrous tissues to ossify, form bone tissue, when injured or spontaneously.
Mutations in ACVR1 have been implicated in this disease.
Gag-pol – Group Antigens (ag)-Pol, A retroviral polyprotein that is cleaved to
create the non-viral envelope proteins required for producing a retrovirus,
including the reverse transcriptase (Pol) and retroviral core proteins (Gag). An
expression construct containing this is used alongside an envelope-producing
construct and the desired retroiviral expression vector to create a replicationdead retrovirus.
HA –Human influenza hemagglutinin, commonly used as an epitope tag. The
tag’s Amino Acid Sequence: YPYDVPDYA
Iowa Black FQ – An IDT (Integrated DNA Technologies)-developed quencher
with an absorbance range of 420 to 620 nm. The main use in this case is to
attachment to oligonucleotides, to quench the activity of the nearby 6-FAM group.
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LDN-193189 – A serine/threonine kinase inhibitor derived from dorsomorphin to
be a more specific inhibitor to BMP/Activin related ALKs.
MTS – 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, a tetrazole that, when present with phenazine
methosulfate (PMS), produces a formazan product with the absorbance range of
490-500 nm, when reduced by cellular enzymes.
qPCR – Quantitative or Real-Time Polymerase Chain Reaction, a quantitative
form of polymerase chain reaction where an fluorescence activity is tested for at
the end of each cycle of PCR, with the activation of a fluorescent dye being
directly linked with each successful polymerase reaction.
SELEX– systematic evolution of ligands by exponential enrichment. An
approach for identifying the binding site of proteins on RNA or DNA in vitro.
shRNA – small hairpin RNA, a short sequence of RNA, usually artificially
produced, to silence the targeted gene through RNA interference/post
transcriptional gene silencing.
TCGA – The Cancer Genome Atlas, http://cancergenome.nih.gov/
TSE – Transcriptional Sequence End, the predicted endpoint for transcription of
a gene locus. In this dissertation, TSE refers to a 5 kb untranscribed region
downstream the endpoint for the purpose of defining the location of ChIP peaks
in reference to nearby gene loci.
TSS – Transcriptional Start Site, the transcriptional start site of a gene locus. In
this dissertation, the promoter region is defined as a 5 kb region upstream of the
transcriptional start site.
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Chapter 1. Introduction
1. MIXL1
MIXL1, Mesoderm Inducer in Xenopus Like 1, is the human ortholog of
Xenopus Mix.1, required for mesoderm development. MIXL1 is the sole human
member of the Mix/Bix homeobox sub-family.

While the Mix/Bix family is

comprised of multiple genes in Xenopus laevis (Mix.1-4, Bix.1-4, and Mixer) and
Danio Rerio (Bon, Mxtx1 and Mxtx2); birds and mammals each contain only one
ortholog for Mix.1 and no pseudogenes (1-3). The Mix/Bix family has been well
characterized as major regulators of mesoderm and endoderm specification in
early embryonic development in Xenopus.

Expression of Mixl1, the mouse

ortholog of MIXL1 was detected at day 5.5 post coitum (dpc) in the visceral
endoderm (3, 4), primitive streak and in the nascent mesoderm between days
6.5-8.0 dpc (3-5).
defects (6).

Mixl1-/- embryos died before days 10.5 dpc with multiple

Enforced expression of Mixl1 in mouse ES cells promoted

mesodermal, hemangioblastic and hematopoietic progenitors (7).
As a paired-type subfamily, Mix/Bix family proteins are characterized by
60 amino acid segments homologous to that of the paired type homeobox
transcription

factors.

Paired-type

homeodomain-containing

proteins

preferentially bind to DNA at a sequence motif of “TAAT”. Mix/Bix family are
classified as Q50 paired-types, denoting both a glutamine in the 50th amino acid
in the homeodomain, and a preference for a 3 nucleotide spacer of sequence
“TGA” between both halves of the dimer motif i.e TAATTGAATTA (8, 9). The
preference to a TAATNNNATTA sequence was confirmed for mouse Mixl1(10).
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While the Mix/Bix family is well characterized to bind as a dimer with other
mesoderm-specific homeodomain-containing proteins, including other Mix/Bix
family members, Gsc and Siamois (11), human MIXL1 was found to interact, in
mammalian a high throughput two-hybrid screen, with homeodomain-containing
proteins associated with a diverse set of lineages, including the neuronalassociated POU4F2, OTX2, and DLX1, thyroid-associated NKX2-1, and dermisassociated ALX4 (12). In the same study, MIXL1 interacted with the basic helixloop-helix transcription factor NEUROD1, implying that MIXL1 may have the
potential to interact with non-homeobox proteins.

2. MIXL1 is regulated by TGF-β/BMP Pathways
One of the developmental roles of the BMP ligand BMP4 is the induction
of mesoderm during early embryogenesis, and in Xenopus, Mix.1 is an
necessary intermediate for BMP4 induction of the mesoderm (1). This translates
to humans as well; when human embryonic stem cells are exposed to BMP4,
mesoderm differentiation is induced (13). Indeed, both Activin A and BMP4 can
induce MIXL1 expression in human embryonic stem cells (14-16), and Mix.1 is
an intermediate for BMP4-mediated dorsal-ventral patterning in Xenopus (17).
The promoter regions for both human MIXL1 and mouse Mixl1 contain multiple
SMAD binding elements (12).
TGF-β ligands have also been implicated in the regulation of MIXL1
expression.

TGF-β signaling can activate Mixl1 expression in mouse in

collaboration with the transcription factor FoxH1 (18), and FoxH1 can collaborate
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with Gsc to suppresses Mixl1 expression (19). MIXL1 may be transcriptionally
regulated by the TGF-β superfamily of cytokines through TGF-β/BMP receptors
to activate the SMAD family of transcription factors.

3. MIXL1 in Hematopoiesis and Hematopoietic Neoplasms
While MIXL1 is well characterized in the role of mesoderm formation
during embryogenesis, its roles in post natal homeostasis have gone
uncharacterized. In adults, MIXL1 is expressed in hematopoietic progenitor cells
(2). This has implicated a potential role of MIXL1 in hematopoiesis, and indeed
loss of Mixl1 in mouse embryonic stem cells leads to significant hematopoietic
defects (20). Additionally, MIXL1 is highly expressed in Hodgkin’s, Burkitt’s and
Diffuse Large B Cell Lymphoma (21), and leukemia and lymphoma cell lines (2),
implying a role in the pathogenesis of hematopoietic neoplasms, leukemia and
lymphoma progression.
In mouse, enforced expression of Mixl1 in hematopoietic stem cells
resulted in a transplantable acute myeloid leukemia (AML) with a 200 day latency
in 100% of mice (22).

Furthermore, enforced expression of Mixl1 in

hematopoietic

conferred

stem

cells

abnormal

self-renewal

potential

to

granulocytic precursors (23). Additionally, viral integration into the Mixl1 locus in
mice was identified as a potential collaborator to p27Kip1 loss in inducing T-cell
leukemia (24).

MIXL1 therefore may play a significant role in a subset of

hematopoietic neoplasms.
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4. Homeobox genes in Acute Myeloid Leukemia
A large body of evidence implicates the deregulation of homeobox genes
is important for the progression of AML and is often associated with the poorer
outcomes. Aberrant expression of both type I clustered homeobox-containing
proteins, including HOXA9 and HOXB3 (25-27), and type II non-clustered
homeobox genes, including HLX and CDX2, have been reported (28-32). Nonrandom chromosomal translocations resulting in homeobox-containing proteins
are also a common occurrence in AML, and further underscore the importance
and leukemogenic potential of aberrant expression of homeobox proteins (33,
34). While homeobox-containing proteins expression is tightly controlled and
each protein is only expressed at a restricted stage of differentiation during
normal

hematopoietic

maturation,

constitutively expressed in AML.

homeobox-containing

proteins

are

A recurrent functional consequence of all

homeobox genes over expression is self-renewal, a limiting step in AML
pathogenesis (35).

While many homeobox genes identified are strongly

associated with AML are considered markers of poor prognosis, whether there is
overlap in expression between many of the identified homeobox proteins in AML
is unknown. Similar hematopoietic-relevant homeobox genes may have a similar
function in transformation of the remaining cases.
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5. NF-κB Pathway in Leukemia and Lymphoma
The NF-κB family includes transcription factors that regulate stress
response, proliferation, apoptosis, cell growth, and immune response.

Each

active NF-κB complex consists of a dimer between a NF-κB/REL protein
including a transactivation domain (RELA, RELB, and c-REL), and one that does
not (NFκB1 or NFκB2).

Of the five NFkb genes, c-REL is a proto-oncogene as

the chicken reticuloendotheliosis viral ortholog v-rel

transforms hematopoietic

cells. (36).
The activation of NF-κB complexes has been implicated in both
hematopoietic progenitor self-renewal and leukemia and lymphoma progression.
In hematopoietic stem cell transplantation, knockout of both NF-κB2 and RelB
impairs engraftment due to increased self-renewal capacity (37). In Diffuse large
B-cell lymphoma, NF-κB complexes are commonly activated, and elevated cREL expression in the germinal center subtype correlates with poor survival (38).
NF-κB complexes are also constitutively active in leukemic progenitor cells and in
acute myeloid leukemia (39).
One of the functional consequences of NF-κB activation is the
transcriptional activation of the BCL2 (B-cell CLL/lymphoma 2) family. The BCL2
family consists of three proteins (BCL2, BCL2A1, BCL2L1), all of which function
as anti-apoptotic factors by inhibiting the release of Cytochrome C release during
caspase-mediated apoptosis.

Overexpression or amplification of BCL2 are

common pro-survival modifications in cancer, and
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recurrent chromosomal

translocations resulting in

constitutive expression of

BCL2

is common

of

diffuse large B-cell lymphoma (40).

6. Clarifying the role of MIXL1 in Acute Myeloid leukemia
While MIXL1 has been implicated in acute myeloid leukemia, little is
known about its overall role in leukemia. I hypothesize that MIXL1 is regulated
by the BMP4 pathway in hematopoiesis and leukemia cell lines to promote
proliferation through transcriptional activation of downstream targets. In the
following pages, I identify a novel direct transcriptional target of MIXL1 in
leukemic cell lines, the proto-oncogene c-REL, by chromatin immunoprecipitation
(ChIP) and mRNA expression analysis. I also identify thatMIXL1 is induced in
normal hematopoietic stem progenitors by BMP4. Consequently, BMP pathway
inhibitor LDN-193189 is sufficient to impair growth in MIXL1-expressing AML
lines in vitro.
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Chapter 2. Materials and Methods
1. Cell Culture
AML cell lines U937, HL-60, OCI-AML2, ML3, and chronic myeloid
leukemia cell line K562, were grown under conditions of 5% CO 2 and 37C in
RPMI 1640 with 10% FBS. AML cell line KG-1 was grown in RPMI 1640 with
20% FBS. Human embryonic cell line HEK-293T was grown in DMEM with 10%
FBS under 5% CO2 and 37C.
Human cord blood hematopoietic stem progenitors cells (CD34)+ from
three subjects denoted 47, 51, and 60, were provided by Drs. Lisa St. John and
Jeffrey Molldrem.

2. Establishment of Overexpression and Knockdown Cell Lines
Inducible expression cell lines for FLAG-HA-tagged MIXL1 were
previously established using U937T cells containing pTET-VP16PURO by
electroporation following a protocol previously described by the lab (41). Clones
used are denoted U937.1MIXL and U937.2MIXL, while an empty vector control is
denoted U937.Control.
Lentiviral Production: Viral particles were generated

in HEK-293T by

transient transfection of the lentiviral expression construct, envelope construct
pCMV-VSV-G, encoding the viral envelop protein VSV-G, and a gag-polencoding construct, at a ratio of 2:1:1 respectively. Lentiviral constructs were
purchased from OpenBiosystems (Pittsburg, PA) and designated as such: MIXL1
KD1 = TRCN0000019155, MIXL KD2 = TRCN0000019156, and c-REL
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Expression = ccsbBroad304_11094. The cells were incubated for 48 hours at
37ºC before harvesting the media containing viral particles. Viral particles were
purified by passage through a 45 µm filter, and stored in -80⁰C until use.
Lentiviral transductions were performed by resuspending 2x105 cells in 1
ml of virus-containing conditioned medium with 8 µg/ml polybrene, and then
incubated at 37⁰C for 24 hours. After the incubation, the cells were pelleted by
centrifugation and resuspended in the growth medium.

Growth assay and

expression experiments were performed 48 hours after transduction.

3. Chromatin Immunoprecipitation
Chromatin Immunoprecipitation was based on the one used by Chadee et
al (42), with the following modifications.

For each U937 cell line, a total of 10 8

cells were cross-linked with 1% formaldehyde in growth media at 37ºC for 20
minutes. Cells were harvested by centrifugation at 3000 RPM for 10 minutes,
and resuspended in 500 μL RIPA lysis buffer. After 10 minutes on ice, the cells
were sonicated 20 times at 4-5 watts for 20 seconds, with a rest time of 40
seconds between each sonication. The samples were then centrifuged for 5
minutes at 4ºC and precleared with 20 μL A/G agarose slurry for 1 hour at 4ºC.
Two aliquots from each lysate was processed as follows (i) Flag-IP: 240 μL of
the lysate, 250 μL lysis buffer, and 8.4 μg mouse anti-flag antibody (anti-Flag-M2,
Sigma), (ii) IgG-IP 240 μL of the lysate, 250 μL lysis buffer, and 8.4 μg mouse
IgG.

The samples were incubated overnight at 4ºC with rotation, and then

incubated for an additional hour with 20 μL A/G agarose slurry. The agarose
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beads were recovered by centrifugation and washed for 15 minutes each in:
RIPA lysis buffer, high salt RIPA buffer, lithium chloride RIPA buffer, and finally
TE prior to Proteinase K and RNAse treatment at 37ºC overnight. The samples
were incubated for 6 hours at 65ºC to reverse crosslinking.

DNA was

precipitated overnight at -20ºC in 75% ethanol, and then washed twice in 75%
ethanol.

For each sample

DNA from a 20 μL aliquot of the pre immune

precipitation lysate diluted with 180 μL TE buffer served as another control for
target amplification. The DNAs were resuspended in 50 μL ddH2O and the PreIP sample was then diluted with 450 μL of ddH2O.
50 ng each of immuno precipitated DNAs from (1) U937 Control IgG-IP,
(2) U937 Control Flag-IP, (3) U937 1MIXL Flag-IP, and (4) U937 2MIXL-IP were
used to construct libraries by the Sequencing and Microarray Facility (SMF) at
MD Anderson Cancer center using the Beckman SPRIworks system. Illumina
analysis pipeline GAPipeline-1.5.0 was used for base calling and alignment to
human genome. Peak calling was done by MACS v1.3.7.1 at pvalue<=1e-5.
Peaks were identified against the human genome (UCSC assembly hg18,
NCBI36) using genome model-based analysis of ChIP-Seq [MACS](43), and
were generated by normalizing to the two control samples in three combinations:
Flag-1MIXL to IgG-Control and Flag-Control, Flag-2MIXL to IgG-Control and
Flag-Control, and Flag-1MIXL and Flag-2MIXL combined to IgG-Control and
Flag-Control. The primary dataset used for analysis was overlapping peaks in all
three analyses. The combined dataset was tested for predicted Paired-Q9
binding motifs(8) using Motif alignment and Search Tool [MAST](44), and
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enriched motifs were identified using Multiple EM for Motif Elicitation
[MEME](45).
Peaks were allocated to genes within a 25kb region, designated as
follows: upstream – 5 to 25 kb upstream of the transcription start site, promoter –
0 to 5 kb upstream of the transcription start site, body – between the transcription
start and end, TSE – 0 to 5 kb downstream of the transcriptional end,
downstream – 5 to 25 kb downstream of the transcriptional end, and distant – not
allocated to a gene.
ChIP-qPCR confirmation was performed by SYBR green quantitative PCR
using primersets for each peak region identified and an exonic c-REL region
primer set for control, as listed in Table 1. For ChIP-qPCR against endogenous
proteins, 5 μg anti-MIXL1-N and anti-MIXL1-C antibodies (2) and anti-MZF1 (sc66991,

Santa

Cruz

Biotechnologies,

Dallas,

TX)

were

used

for

immunoprecipitation.

4. Global Expression Analysis
The original microarray analysis was performed previously by Dr. Hong
Liang. To identify potential targets of the MIXL1 transcription factor, Dr. Liang
performed global expression profiling analysis on MIXL1-expressing cells by
microarray. The cell lines 1MIXL and Control were cultured without TET for 24
hours at 5X104 cells/mL. RNA was extracted from 5x106 cells by RNEASY
Minikit (QIAGEN, Valencia, CA).

Extracted RNA was hybridized against a

Human Genome Affymetrix HG133A Microarray (Affymetrix, Santa Clara, CA).

10

For analysis, dChip analyzer software (46) was used, normalizing the
1MIXL dataset to the Control dataset, and gene expression models were
obtained through PM (Perfect Model)-only approach. Differentially expressed
genes were defined as genes in which the difference between the detected
expression levels was at least 100, and the ratio was at least 1.2.
The networks analyses were generated through the use of Ingenuity
Pathway Analysis (Ingenuity Systems, www.ingenuity.com).

5. RT-QPCR
RNA was purified using RNeasy Mini Kit from 5x106 cells for each line.
200 ng from each sample was then reverse transcribed and diluted 10-fold. The
samples were assayed by qPCR in triplicate using Taqman primers obtained
from Applied Biosystems/Life Technologies (Carlsbad, CA) and Integrated DNA
Technologies (Coralville, Iowa), as denoted in Table 2, and then quantified by
delta-delta-CT method.
For CD34+ cells, RNA was harvested in triplicate from ~2500 cells by
RNeasy Micro Kit + (QIAGEN, Valencia, CA) 2 hours after addition of either 50
ng/ml BMP4 (314-BP, R&D Systems, Minneapolis, MN) or 2 ng/ml TGF-β1
(Sigma-Aldrich) in X Vivo-15 medium (Lonza, Allendale, NJ), then 100 ng from
each sample was reverse transcribed and assayed.
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Table 1. Primer sets used for ChIP-qPCR. Listed are the primers used for
quantitative PCR analysis of the Chromatin Immunoprecipitation techniques.
Each primer set is will generate a 100-200 bp product encoded near the center of
the ChIP-Seq identified gene locus peak, with exception of Rel-Int-F/-R, which
covers a 100-200 bp region internal of the REL gene locus not enriched in the
ChIP-Seq analysis.
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Primers used ChIP-qPCR
Rel-Int-F

5-TTACCAGGATTTTGGCAAGG-3

Rel-Int-R

5-CAGGCAGTTTGGGGATAAGA-3

Rel-F

5-GGAACCACCTCTCGAAAACC-3

Rel-R

5-TCCAGGTTGTTCTTCCGAGT-3

EIF1-F

5-TGACTCCGTGGGTAGTAGGG-3

EIF1-R

5-CCTTCTTGACCCTGTTGCAT-3

SLC39A13-F

5-CCTGAGGTTCCCAGTGAAAA-3

SLC39A13-R

5-GAGGACTACTGTGCGCTCCT-3

SMYD5-F

5-TTCCCCCTTTCATGACTCTG-3

SMYD5-R

5-CTCAGCTCAGTCCCCAAGAG-3

ZP3-F

5-ACCTCAGCCTCCCCAGTAGT-3

ZP3-R

5-TTGATCCAAAAGCAGCTGAA-3
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Table 2. Probe-sets used for RT-QPCR analysis. Listed are the probes used
for reverse transcription-coupled quantitative PCR for each of the respective
genes. Probes for MIXL1, REL, BCL2L1, and BCL2A1 were supplied by Applied
Biosystems (Carlsbad, CA), while probes for APBB2, IL18R1, and PCGF2 were
customized and ordered from Integrated Integrated DNA Technologies
(Coralville, Iowa), to be fully compatible with TaqMan analysis.

14

Probes used for qPCR
MIXL1

Hs00968440_m1 TaqMan, Applied Biosystems

REL

Hs00231279_m1 TaqMan, Applied Biosystems

BCL2L1

Hs99999146_m1 TaqMan, Applied Biosystems

BCL2A1

Hs00187845_m1 TaqMan, Applied Biosystems

EGR1

Hs00152928_m1 TaqMan, Applied Biosystems
Probe
5-CTCCCCAAATCCCGACTGTGTCT-3
5' 6-FAM, 3' Iowa Black FQ
Primer1
5-GATGGGTAGAGATGGCAGAAG-3
Primer2
5-GGATCAGGTACATGTCTTTCCC-3
Integrated DNA Technologies
Probe
5-CCTCCAGGCACTACATCCCTTTCAA-3
5' 6-FAM, 3' Iowa Black FQ
Primer1
5-CACCTTTGCTGTGGAGATTTTG-3
Primer2
5-TCTTCGGCTTTTCTCTATCAGTG-3
Integrated DNA Technologies
Probe
5-TGGACATCGCCTACATCTACCCCT-3
5' 6-FAM, 3' Iowa Black FQ
Primer1
5-GACGAGCCACTGAAGGAATAC-3
Primer2
5-GCTGGACACGGTACTTGAG-3
Integrated DNA Technologies

APBB2

IL18R1

PCGF2
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6. Co-Immunoprecipitation
107 cells of U937-1MIXL were lysed with 1 ml ice-cold RIPA buffer
(150 mM NaCl, 1.0%. NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris
(pH 7.5), 5 µg/ml leupeptin, 8 µg/ml aprotinin, 1 mM PMSF, 0.7 µg/ml pepstatin A
and 1 mM EDTA (pH 8.0)). 900 µl of the lysate was precleared by incubation with
protein A/G-agarose beads for 1 hour at 4ºC. 5 µg M2 anti-flag monoclonal
antibody and 5 µg mouse IgG antibody were each added to separate aliquots of
450 µl cleared lysate, and incubated for 2 hours at 4ºC. 20 µl of protein Gagarose beads was added to the immune complexes and incubated for 1 hour at
4°C. After four washes with NET-N buffer (100 mM NaCl, 1 mM EDTA (pH 8.0),
20 mM Tris (pH 8.0), 0.2% NP-40, 5 µg/ml leupeptin, 8 µg/ml aprotinin,
1 mM PMSF, 0.7 µg/ml pepstatin A), the precipitated proteins were eluted in 20 µl
of 2 SDS loading buffer (100 mM Tris (pH 6.8), 200 mM DTT, 4% SDS, 0.2%
bromophenol blue, 20% glycerol) and then resolved by 10% NuPAGE gel
(Invitrogen, Carlsbad, CA).

7. Immunoblotting
Cells were lysed in Whole Cell lysis buffer (20 mM Tris, 250 mM NaCl, 2
mM EDTA, 1% Triton X-100, 1 mM DTT, 2 µg/ml Aprotinin, 2 µg/ml Leupeptin, 2
µg/ml Pepstatin A, 1 mM NaVO3, 1 mM PMSF), then denatured in 4x SDS buffer
at 90ºC for 10 minutes, then resolved on 10% NuPAGE gel (Life Technologies)
using MOPS buffer, and transferred to a PVDF membrane (GE Healthcare,
Pittsburgh, PA).
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Membranes were first blocked by incubation in TBS-T (50 mM Tris, 150
mM NaCl, and 0.05% Tween 20 adjusted to pH 7.6) with 5% milk for one hour,
after which they were washed in TBS-T two times for two minutes.

The

membrane was then incubated with the first antibody for 2 hours 2% milk TBS-T
at room temperature then washed in TBS-T two times for 5 minutes, then once
for 15 minutes. The blot was then incubated with the secondary antibody in 2%
milk TBS-T for 1 hour, followed by another round of washes in TBS-T. Blots
were visualized using Amersham ECL western blotting detection reagent (GE
Healthcare) with 5 minutes of film exposure.
Primary antibodies used were anti-MIXL1-N at 1:1500, MZF1 (sc-66991,
Santa Cruz Technologies, Dallas, TX) at 1:100, and beta-actin (Sigma Aldrich) at
1:5,000. The secondary antibodies used were anti-rabbit-HRP (GE Healthcare)
at 1:10,000 for the majority of primaries and anti-mouse-HRP (GE Healthcare) at
1:7,000 for the beta-actin primary antibody.

8. Luciferase Reporter Assay
Luciferase constructs were generated by PCR amplification of segments
of the c-REL peak region identified by ChIP-Seq.

Promoter segments were

amplified from genomic DNA extracted from human placenta with the primers
listed in Table 3 and sub-cloned into the pBV-Luc vector between Mlu1 and
EcoR1 sites.

Each luciferase reporter vector insert was then confirmed by

sequencing. 293T cells were transfected with 200 ng of expression vector, 200
ng of luciferase vector, and 0.2 ng Renilla Luciferase vector by Lipofectamine
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Table 3. Primers used for REL Promoter Luciferase construct construction.
Listed are the primer sets used to generate the REL promoter region inserts for
construction of p-BV-Luc-based luciferase vectors for use in the luciferase
reporter assay. Each forward primer contains a Mlu1 target sequence and each
reverse primer contains an EcoR1 target sequence for restriction digest. Primers
were used in pairs. First set: Rel-R-EcoR1 paired with Rel-FM-130, Rel-FM-500,
Rel-FM-700, and Rel-FM-944, with the Forward primer name denoting length of
product. Second set: Rel-FM-700 paired with Rel-RE-150, Rel-RE-200, Rel-RE300, and Rel-RE-580, with the Reverse primer pair denoting length of product.
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Primers used for Luciferase Reporter Construction
Rel-R-EcoR1

5-ctgt-gaattc-CGCAGTCAGTCAGTCAGGAG-3

Rel-FM-130

5-ctgt-acgcgt-AGAATTCAGGGGTTGGGAAG-3

Rel-FM-500

5-ctgt-acgcgt-GGAAGAACAACCTGGAGGAG-3

Rel-FM-700

5-ctgt-acgcgt-GAACCACCTCTCGAAAACC-3

Rel-FM-944

5-ctgt-acgcgt-GGAGCTTTGGAGTCAGACAA-3

Rel-RE-150

5-ctgt-gaattc-CAGGTTGTTCTTCCGAGT-3

Rel-RE-200

5-ctgt-gaattc-GGCTAGCAGCGTGAGAAGG-3

Rel-RE-300

5-ctgt-gaattc-GACGCAGCAACCCTCACC-3

Rel-RE-580

5-ctgt-gaattc-AACCCCTGAATTCTTGCAC-3
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(Invitrogen, Grand Island, NY). The activity was then tested by Dual Luciferase
Reporter Assay System (Promega, Madison, WI) 48 hours post-transfection.

9. MTS Assay
The growth assay for comparison of knockdown cell lines were performed
by plating 3x104 cells/well for each line into a 96-well plate in triplicate, then
testing

the

culture

growth

by

MTS

(3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay every 24 hours
of incubation.
For comparative analysis of the effects of doxorubicin on U937 MIXL1overexpressing lines, the three clones (Control, 1MIXL, and 2MIXL) were seeded
to a 96-well plate at a density of 3x104 cells/well. Doxorubicin (Sigma-Aldrich, St.
Louis, MO) was added to each well at 0 – 2 µM in triplicates, for 24 hours before
MTS treatment.
To measure survival response to high concentrations of LDN-193189,
each cell line was plated at 3x104 cells/well on 96-well plates and treated with
either 3 µM LDN-193189 (Cellagen, San Diego, CA) or the equivalent
concentration of DMSO in triplicate. Each line was then tested by MTS assay
immediately, then again every 24 hours.
For the dose response experiments for LDN-193189, each line was plated
at 3x103x104 cells/well on 96-well plates and treated with 0 – 0.7 µM LDN193189 in triplicate. The cells were then incubated for 4 days, with additional
treatments of 0 – 0.7 µM LDN-193189, before being tested by MTS assay.
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The MTS assay was performed by the CellTiter 96 AQueous NonRadioactive Cell Proliferation Assay kit (Promega) with an incubation time of 1
hour.

10. Analysis and Data mining
TCGA AML database (47) was accessed and analyzed through the
cBioPortal (48, 49) for cases either with a mutation, copy-number alteration, or
expression change of 2-fold or over (1.0 threshold).
Identification of transcription factor binding motifs in the c-REL promoter
was performed using TFSearch. (50)
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Chapter 3. Results
1. Characterization of AML cell lines with overexpression of MIXL1
To identify the role of MIXL1 in AML, I used FLAG-HA-tagged MIXL1
inducible expression cell lines established in U937, a hystiocytic lymphoma,
previously created in the lab, denoted U937.1MIXL and U937.2MIXL with an
empty vector control line U937.Control.

While these clones were initially

established with MIXL1 expression inducible by tetracycline withdrawal, after
multiple passaging both clones exhibited enforced MIXL1 expression regardless
of tetracycline induction, and were subsequently treated as overexpression lines.
To determine if the levels of MIXL1 protein in the overexpression lines was
comparable to endogenous protein levels in leukemia, I compared the protein
levels of 1MIXL and 2MIXL to that of three AML lines, the high-expressing KG1
and ML3 and low-expressing HL60, where MIXL1 protein levels had already
been tested (2), the previously untested AML OCI-AML2, and the CML line K562
(Figure 1). Protein expression in 1MIXL and 2MIXL was comparable to that of
the expressing cell lines K562, KG1, ML3, and OCI-AML2, while U937.Control
and HL60 had no detectable levels of MIXL1.
To test if MIXL1 infers a survival advantage in leukemic cell lines, I
performed a MTS assay comparing the survival of the U937 subclones under 24
hour exposure to 0 – 2 µM of the leukemia chemotherapy drug doxorubicin
(Figure 2). After 24 hours of treatment, doxorubicin had a LD50 of 0.25 µM for the
U937.Control line and 0.75 µM for 1MIXL and 2MIXL, with only the Control line
nearly completely eliminated at the 1.75 µM concentration of doxorubicin.
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Figure 1. Stable transfectants of U937 cells express MIXL1 at levels similar
to endogenous protein in AML cell lines.

MIXL1 detected by probing 30ug

whole cell lysates resolved on SDS-PAGE, transferred to PVDF membrane, with
rabbit antibodies against N–terminal epitope of MIXL1 and β actin for loading
control.
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MIXL1
B-actin
Control 1MIXL 2MIXL HL60 K562
U937
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KG1

ML3 OCIAML2

Figure 2. MIXL1 expression reduces sensitivity of U937 cells to
doxorubicin. The cell lines were treated with 0 µM to 1.75 µM Doxorubicin on
Day 0. Cell survival was measured at 24 hours by MTS assay. Absorbance of
untreated cells was normalized to 1. Relative viability at varying concentrations
of doxorubicin is denoted.
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2.

ChIP-Seq

analysis

of

MIXL1

overexpression

lines

to

identify

transcriptional targets
As few transcriptional targets for MIXL1 in hematopoiesis have been
identified, I performed ChIP-Seq in our overexpression clones to identify
transcriptional targets of MIXL1.

Flag-HA-MIXL1 and bound DNA segments

were immunoprecipitated from both 1MIXL and 2MIXL by FLAG antibodies,
alongside two control samples of FLAG-IP in U937.Control with no expected
target, and IgG-IP in U937.Control. The sequenced samples were then aligned
to the genome and analyzed in different pairwise combinations by Dr. Yue Lu
and Dr. Shoudan Liang: 1MIXL-Flag normalized to Control-Flag and ControlIgG, 2MIXL-Flag normalized to Control-Flag and Control-IgG, 1MIXL-Flag and
2MIXL-Flag combined then normalized to Control-Flag and Control-IgG. Each of
these sets identified over 1500 peaks, though only a small subset containing 179
peaks was present in all four groups (Figure 3). The overlap subset shared by all
three groups was isolated and used in further studies (Appendix).
As a homeobox transcription factor, we expected MIXL1 to primarily
interact with promoter regions of gene loci. To determine if this was the case,
Yue Lu and Dr. Shoudan Liang identified where each peak in the 179 peak set
was in relation to its nearest gene loci (Appendix and Figure 4). Out of the 179
peaks, 64% of the peaks localized to the promoter region (within 5 kb upstream
of the transcription start site), 8% were localized to transcribed gene regions, 4%
were between 25 kb and 5 kb upstream of the transcription start site, 1% were
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Figure 3.

Multiple analyses of MIXL1-ChIP-Seq identify 179 high-quality

peaks. Venn diagram of all the peaks identified using three different analyses of
the two experimental (Flag immunoprecipitation in U937 1MIXL or 2MIXL) and
two negative control (Flag or IgG immunoprecipitation in U937 Control) : 1MIXL
vs Controls, 2MIXL vs Controls and 1MIXL+2MIXL vs Controls. Out of the peaks
identified, 179 peaks were significantly enriched in all sets.
This figure was generated as part of the statistical analysis performed by Dr. Yue
Lu and Dr. Shoudan Liang for ChIP-seq.
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Figure 4. The majority of peaks for MIXL1 identified by ChIP-Seq localize to
the Promoter region. Pie chart depicting the localization of MIXL1 to human
genome. Peaks were classified based on distance to nearest transcribed gene
locus, using the following criteria:

upstream – 5 to 25 kb upstream of the

transcription start site, promoter – 0 to 5 kb upstream of the transcription start
site, body – between the transcription start and end, TSE – 0 to 5 kb downstream
of the transcriptional end, downstream – 5 to 25 kb downstream of the
transcriptional end, and distant – not allocated to a gene. Note that majority of
peaks (67%) localized to gene promoters.
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within 5 kb of the transcription sequence end, and 3% were between 25 kb and 5
kb of the transcription sequence end. 20% of the peaks were classified as not
being within 25 kb of any known genes.
As stated in the introduction, MIXL1 is a paired type homeobox with a
previously characterized predicted motif (8). To determine if this motif is how
MIXL1 is bound to the identified motif locations, Dr. Yue Lu and Dr. Shoudan
Liang analyzed the 179 peak set (Appendix) and a comparable randomized DNA
fragment set for two different variants of the motif using the Motif alignment and
Search Tool [MAST] (44) (Figure 5).

Neither motif was significantly over-

represented in the 179 peak set compared to the random set; therefore, the
expected motif for MIXL1 is not enriched in our peak set. To characterize what
motifs were enriched in our peaks, Dr. Yue Lu and Dr. Shoudan Liang next
performed Multiple EM for Motif Elicitation [MEME] (45) for the sequences 200
base-pairs around each peak summit. The two highest peak motifs (Figure 6)
are CG-rich and show no similarity to the AT-rich predicted homeobox motifs
(TAAT); instead, they are more similar to zinc finger motifs.
To confirm the peak regions enriched in SET4 of the ChIP-seq analysis, I
reanalyzed five of those regions, peaks near EIF1, c-REL, SLC39A13, SMYD5,
and ZP3, by ChIP-qPCR in U937.Control, 1MIXL and 2MIXL by ChIP-qPCR
using the Flag-antibody for immunoprecipitation (Figure 7). While each peak was
enriched by ChIP-qPCR, only EIF1, SLC9A13, and SMYD5 had the scale of
enrichment over the control samples that were seen in the ChIP-seq. This may
be due to variability between the techniques.
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Figure 5. Predicted MIXL1 motifs are not enriched in U937 overexpression
MIXL1 ChIP-seq Peaks.

Motif1 and Motif2 were previously characterized

putative MIXL binding motifs, and were searched against the stringent set of
peaks (Appendix) at various distances (1000bp, 500bp, 200bp, or 100bp as
listed) from the peak apex (top lines) and from the center of randomized
sequences of the same length (bottom lines) , at either a p-value of 1e-4, 5e-4, or
1e-3. In all cases, the likelihood of finding the MIXL1 binding motif was either not
statistically significantly different or even lower than the likelihood of identifying
the motif in randomized sequences, therefore the MIXL1 binding motif is not
enriched in this dataset.
This figure was generated as part of the statistical analysis performed by Dr. Yue
Lu and Dr. Shoudan Liang for ChIP-seq.
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Figure 6. The most commonly occurring motifs in the ChIP-seq peaks are
Zinc-Finger binding motifs. Motif1 and Motif2 were the two most statistically
significant common motifs generated using the Multiple EM for Motif Elicitation
[MEME] against the peak regions identified in the ChIP-seq analysis (Appendix).
Both motifs are C/G-heavy regions of similarity to known zinc finger motifs.
This figure was generated as part of the statistical analysis performed by Dr. Yue
Lu and Dr. Shoudan Liang for ChIP-seq.

35

MOTIF 1 width = 15 sites = 65 E-value = 1.1e-027

MOTIF 2 width = 15 sites = 112 E-value = 3.6e-015
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Figure 7. ChIP-qPCR analysis of selected gene-associated peaks confirms
enrichment.

ChIP of 5 candidate peaks with FLAG antibodies identified by

ChIP-Seq (EIF1, c-REL, SLC39A13, SMYD5, ZP3) showed specific MIXL1
binding both 1MIXL and 2MIXL clonal ChIP with normal mouse IgG served us
control. Error bars represent standard deviation between triplicates. * denotes p
value <0.05. The chart below is the ChIP-seq results for the constrained (179peak) dataset for each of the peaks tested, for comparison.
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ChIP-Seq Results for selected Peaks
Gene
Peak Location
Enrichment
EIF1
chr17:37097849-37099490 7.55
REL
chr2:60961441-60962652 9.79
SLC39A13
chr11:47385814-47387193 6.87
SMYD5
chr2:73293129-73293533 7.38
ZP3
chr7:75905120-75905486 20.74
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3. Global Expression Profiling of MIXL1 overexpression to confirm
transcriptional targets
To better identify direct transcriptional targets of MIXL1, I took a previous
global expression profiling experiment performed in the lab on U937.Control and
1MIXL using the U133 Plus 2.0 microarray by Dr. Hong Liang and reanalyzed it.
To confirm the microarray analysis, a small subset of genes was tested by RTqPCR in U937.Control 1MIXL and 2MIXL (Figure 8). While the expression of
APBB2 and EGR1 were comparable between both methods at approximately -2fold and +2-fold change, respectively, IL18R1 expression was significantly higher
in 1MIXL by qPCR at 3.5-fold in comparison to the 2.6 identified by microarray.
Of specific note is c-REL, a gene also identified by ChIP-seq as a putative MIXL1
transcriptional target, where both methods found a 1.66-fold increase in 1MIXL,
and interestingly 2MIXL1 expressed 3.5-fold over U937.Control by qPCR.

4. c-REL as a transcriptional target of MIXL1
Since c-REL was identified as a putative transcriptional target of MIXL1 by
both ChIP-Seq and global expression profiling, I decided to get a broader look at
the expression of the overall NF-κB pathway (Figure 9). In the NF-κB pathway,
NFκB1 or NFκB2 herterodimerize with RELA, RELB, or c-REL to transcriptionally
regulate downstream targets, with the most common and best studied dimer pair
being the RELA-NFκB1 dimer. One of the common transcriptional targets of the
NF-κB dimers is the anti-apoptotic BCL2 family (BCL2, BCL2L1, and BCL2A1).
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Figure 8. RT-qPCR confirms change of expression in selected genes as
identified by Microarray. Quantitative RT-PCR confirms expression changes of
selected genes identified by global expression profiling. Quantitative RT-PCR
showing differences in gene expression between U937 control, 1MIXL and
2MIXL. Transcript levels were normalized to 18srRNA. Error bars represent
standard deviation between triplicates. * denotes p value <0.05. The chart below
is the Micorarray results for the 5 genes tested, for comparison.
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Microarray Results for selected genes
probe set
gene
Accession
216747_at
APBB2
AK024871
201694_s_at
EGR1
NM_001964
206618_at
IL18R1
NM_003855
240752_at
PCGF2
AW510760
206035_at
REL
NM_002908
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EntrezGene
323
1958
8809
7703
5966

Fold Change
-2.45
2.78
2.63
5.65
1.66

Figure 9. The NF-κB pathway is regulated by MIXL1. The NF-κB pathway is
regulated by MIXL1.

Output from HG133A affymetrix microarray expression

profiling was analyzed by Ingenuity Pathway analysis software (IPA).

Green

denotes decreased expression and red denotes increased expression relative to
U937.control.
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The activity of these NF-κB dimers can be inhibited by binding with IκB family
proteins (NFKBIA/B/E), which block nuclear localization of the dimer.

In the

global expression profile under MIXL1 overexpression in 1MIXL, all these genes
are differentially regulated: the IκB family members and both components of the
abundant NF-κB dimer (RELA and NFκB1) are down-regulated, while the less
abundant NF-κB members c-REL and RELB and the anti-apoptotic BCL2L1 and
BCL2 are up-regulated.

The anti-apoptotic BCL2A1, however, was down-

regulated.
To confirm the change of expression characterized in the global
expression profiling for c-REL, BCL2A1 and BCL2L1, I analyzed RNA expression
levels by RT-qPCR between U937.Control, 1MIXL and 2MIXL (Figure 10).
Expression of c-REL increased approximately 1.8-fold in 1MIXL and 3-fold in
2MIXL, in agreement with the previous run (Figure 8); BCL2L1 expression
increased approximately 2-fold in each line in confirmation with the microarray
results, while BCL2A1 expression increased approximately 2-fold as well,
raising the possibility of a potential technical difference between the two assays.
While I have identified c-REL promoter region as a target for MIXL1, it is
possible that the perceived interaction is either an artifact of the Flag antibody or
unique to U937 cells. To test both of these possibilities, I performed ChIP-qPCR
on the endogenous C-REL promoter in the AML cell line KG1 using both our Nterminal and C-terminal MIXL1 antibodies (Figure 11). In both cases, the c-REL
promoter was enriched: 3-fold for MIXL-N and 2-fold for MIXL-C, while the
internal genomic locus was not.
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Figure 10. MIXL1 expressing clones show enhanced transcript levels for cREL, BCL2A1, and BCL2L1.

Quantitative RT-PCR results showing the

difference in expression between U937control, 1MIXL and 2MIXL for c-REL,
BCL2A1, and BCL2L1. Expression was normalized to 18srRNA transcript levels.
Error bars represent standard deviation between triplicates. * denotes p value
<0.05
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Figure 11. ChIP localizes endogenous MIXL1 to c-REL promoter in KG1
cells.

Quantitative genomic PCR analysis shows specific enrichment of

endogenous MIXL1 immunopreciptated with either N-terminal or C-terminal
MIXL1 antibodies,on the c-REL promoter whereas an internal locus within the cREL gene showed no MIXL1 occupancy.

Error bars represent standard

deviation between triplicates. * denotes p value <0.05.
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5. MIXL1 knockdown in KG1 represses c-REL and BCL2A1/L1 expression
To confirm MIXL1 regulation of c-REL and its downstream targets, I
knocked down MIXL1 expression by shRNA lentiviral transfection in the highMIXL1 expression AML cell line KG1, and then attempted to reverse the
phenotypes by enforcing expression of c-REL. I first tested the expression of
MIXL1, c-REL, BCL2A1, and BCL2L1 under knockdown of MIXL1 and enforced
expression of c-REL by RT-qPCR (Figure 12). Under MIXL1 knockdown, MIXL1
expression is down to 0.25-fold, while expression of c-REL, BCL2A1, and
BCL2L1 down to about 0.6-fold, 0.5-fold, and 0.7-fold, respectively. With the
enforced expression of c-REL, expression of c-REL, BCL2A1, and BCL2L1
increase approximately 2-fold, regardless of MIXL1 expression level.
To identify if loss of MIXL1 affects the growth rate of KG1 cells, I assayed
the knockdown lines over the course of four days for growth by MTS assay
(Figure 13). While the control shRNA cell line and REL-enforced expression line
grew at a stable rate over 4 days, the knockdown lineages had lower cell counts
than the starting count at 24 hours before recovering to a stable growth rate by
day four.

6. MZF1 and MIXL1 interact with the c-REL promoter
From the ChIP-seq analysis, I have identified the c-REL promoter as a
binding target for MIXL1; however the peak region identified is over 1000 basepairs long, and is lacking in putative MIXL1 motifs.
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These details pose the

Figure 12. Knockdown of MIXL1 decreased while enforced expression of cREL increased c-REL, BCL2A1, and BCL2L1 transcript levels.

MIXL1

shRNA lentivirus, c-REL retrovirus were transduced into KG1 cells. RT-qPCR in
triplicates was performed on RNAs isolated 48 hours after transduction.
Expression was normalized to 18srRNA levels, and error bars represent standard
deviation between triplicates. * denotes p value <0.05
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Figure 13. c-REL over expression rescues of MIXL1 knockdown mediated
growth arrest in KG1 cells. Growth was measured by MTS assay every 24
hours over a 4 day period in KG1 cells transduced with MIXL1 shRNA lentivirus
and c-REL retrovirus. Absorbance was normalized to that of a non-transfected
control sample.
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question: what part of this region is required for MIXL1 interaction and what else
is required for it? To answer this question, I first tried to identify which region of
the peak MIXL1 needs to regulate c-REL expression by performing a luciferase
reporter assay with nested deletions of the c-REL promoter.

By subcloning

genomic fragments of the c-REL promoter generated by PCR (Figure 14, 130 to
944), I generated luciferase constructs in the backbone pBV-Luc. The luciferase
constructs were then co-transfected into HEK293T cells with a MIXL1 expression
construct, a homeoboxless truncated MIXL1 expression construct, or an empty
expression vector; the cells were tested for luciferase activity. Of these first sets,
only the 700 base-pair and 944 base-pair promoters were significantly induced
by full-length MIXL1. To narrow down the region further, I took the N-terminus
region of the 700 base-pair promoter insert and extracted progressively shorter
segments of the promoter in it (Figure 14, 550 to 150).

The only promoter

segment that was significantly induced by full-length MIXL1 was the 550 basepair segment.
To identify potential binding partners for MIXL1 that are required for c-REL
transcriptional regulation, I searched the 550 base-pair region of the c-REL
promoter for known transcription factor binding motifs (Figure 15). The motifs
identified included 2 NF-κB motifs, a RUNX1 motif, 2 Sp1 motifs, and 4 MZF1
motifs. As MZF1 (myeloid zinc finger 1) is a transcription factor associated with
the myeloid lineage and implicated in myeloid leukemia (51, 52), it may be
expressed in MIXL1 expressing cells and may in fact have a synergistic role. To
determine if MIXL1 and MZF1 are actually interacting, I performed co-
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Figure 14. MIXL1 interacts with the center of the identified peak region of
the REL promoter. (Above) c-REL promoter peak region identified by ChIPSeq, as generated by UC Santa Cruz genome browser is shown. The location
and size of each promoter fragment used for the luciferase reporter assay is
displayed underneath. (Below) MIXL1 binds to a 550 bp region within the c-REL
promoter. Regions of the DNA depicted in 5A were cloned into the reporter
vector pBV-Luc luciferase, transiently co-transfected into HEK293T with MIXL1,
MIXL1 Homeobox-less, or empty expression vector. Equal amount of Renalia
Luciferase co-transfected with the reporter constructs allowed normalization.
Luciferase activity of each combination was tested after 48 hours in triplicate.
Error bars represent standard deviation between triplicates. * denotes p value
<0.05
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Figure 15.

Known Transcription Factor Binding Motifs in the REL

Promoter. A visual representation of the location of identified transcription factor
binding motifs by TFSearch in the 550 bp REL promoter identified by luciferase
reporter assay. Of note, the most prevalent motif in this region is the MZF1 zinc
finger binding motif (marked in blue), which is present in four locations.

57

58

immunoprecipitation by anti-Flag antibodies in 1MIXL, using a mouse IgG as a
control then blotted it with a MZF1 antibody (Figure 16). The expected MZF1
band (~82 kDa) was present in the 1MIXL lysate and Flag-immunoprecipitation
but not the IgG-immunoprecipitation, implicating that MIXL1 and MZF1 may form
a complex.
To determine if MZF1 binds to the c-REL promoter in the expected region,
I performed ChIP-qPCR analysis using the c-REL promoter and intron primersets
to probe MZF1-immunoprecipitated genomic DNA from cell line 1MIXL (Figure
17). The promoter region was enriched approximately 2.5-fold in the MZF1immunoprecipitated fraction, while the intronic control region was not enriched.

7. MIXL1 is preferentially induced

by BMP4 in human CD34+ cord blood

hematopoietic stem progenitor cell
MIXL1 has previously been described as a transcriptional target of SMAD
proteins (53) through the canonical TGF-β and BMP signaling pathways.

To

identify whether the TGF-β or BMP is the relavant ligand in hematopoiesis, I
treated CD34+ hematopoietic progenitor cells with either 2 ng/ml of TGF-β1 or 50
ng/ml BMP4, and tested the relative mRNA levels of MIXL1 after 2 hours (Figure
18). BMP4 was able to significantly activate MIXL1 expression relative to the uninduced CD34+ samples by about 2-fold, while TGF-β had no effect on MIXL1
expression.

This implicates BMP4 to be a preferred regulator of MIXL1

expression in hematopoiesis.
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Figure 16.

MZF1 is identified by co-immunoprecipitation of Flag-tagged

MIXL1 in U937. Co-immunoprecipitation assay against Flag-HA-MIXL1 using an
anti-Flag antibody in 1MIXL, and using an anti-MZF1 antibody to probe the
immunoblot,

with

preclear

sample

as

the

positive

control

and

IgG-

immunoprecipitated sample as the negative control. MZF1 was detected in the
preclear lysate and Flag-IP fraction, but not the IgG sample.
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Figure 17. MZF1 binds to the same locus as MIXL1 on c-REL promoter.
Quantitative PCR analysis of the identified c-REL promoter region and c-REL
intron control region, comparing the abundance of each genomic locus
immunoprecipitated by either IgG or MZF1 antibodies, normalized to a standard
curve. Error bars represent standard deviation between triplicates. * denotes p
value <0.05
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Figure 18. BMP4 induces MIXL1 in CD34+. MIXL1 expression increased 2fold in CD34+ cells treated with BMP4, than untreated or cells treated with TGFβ. CD34+ HSPCs from three cord blood donors (47, 51, 60) were treated with
either 50 ng/ml BMP4 or 2 ng/ml TGF-β1 for 2 hours. MIXL1 transcript levels
were quantified by RT-qPCR using 18srRNA as normalization control. Error bars
represent standard deviation between triplicates and * denotes p value <0.05.
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8. MIXL1 expressing cells are sensitive to the BMP inhibitor LDN-193189
As MIXL1 is regulated by the BMP pathway, I postulated that MIXL1expressing lines may have increased sensitivity to BMP pathway inhibition. To
inhibit BMP pathway activation, I used the ALK2/3/6 (ACVR1, BMPR1A, and
BMPR1B) inhibitor LDN-193189. Four high MIXL1-expression cell lines (OCIAML2, KG1, ML3 and K562), and two low MIXL1-expression lines (U937 and
HL60) were exposed to a single treatment of 3 µM LDN-193189 before a 4 day
incubation, with the relative survival assayed by the MTS analysis (Figure 19).
By day 1, the high expression lines were no survival was detected in the LDN193189 treated aliquots, while the growth of the low-expression lines was
diminished compared to the untreated aliquots. However, on the following days,
HL60 and U937 cell cultures have begun to recover, while the high-expressing
lines stay undetectable.
To further characterize the sensitivity to LDN-193189 in high MIXL1expression cell lines, I performed a dose response analysis on each of the 6 lines
over a 0-700 nM

range of LDN-193189. Due to the short half-life of LDN-

193189, the medium was changed every 24 hours, and relative survival was
assayed them by MTS after four days (Figure 20). The number of cells in the
low-expression lines U937 and HL60 were constant across all concentrations of
LDN-193189, suggesting no significant change in growth rate, whereas in the
high-MIXL1 expression lines, there is a significant decrease between 100 nM and
200 nM in culture viability.
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Figure 19. High MIXL1 expression cell lines are sensitive to 3 µM LDN193189. 3 µM of LDN-193189 was cytotoxic to OCI-AML2, ML3, KG1 and K562
in contrast to U937 and HL60cells. Each cell line was treated with vehicle or 3
µM LDN-193189 on Day 0, and viability measured every 24 hours by MTS assay,
in triplicate. Absorbance was normalized to that of a vehicle-only sample.
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Figure 20. High MIXL1 expression cell lines are sensitive to consistent
exposure of LDN-193189 for 4 days. OCI-AML2, ML3, KG1 and K562 were
sensitive to 200 nM LDN-193189, while low MIXL1 expression lines U937 and
HL60 were unaffected. Each cell line was treated with 0 nM to 700 nM LDN193189, replenished every 24 hours with fresh drug or control medium for 4
days. Viability on day 4 was assayed then tested by MTS assay in triplicate.
Absorbance was normalized to that of control vehicle-only treated samples.
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9. Endogenous MIXL1 in AML Patients
To determine if MIXL1 is overexpressed in patient samples, I analyzed the
TCGA AML patient sample dataset for at least 2-fold change of expression,
chromosomal modification, or mutation of MIXL1 by the cBioPortal, AMLassociated homeobox transcription factors CDX2 (30), HLX(28), HOXA9 (27),
and NF-κB pathway members c-REL, BCL2, BCL2A1, and BCL2L1 (Figure 21).
MIXL1 was amplified or up-regulated in 13% of the total AML cases, while only
12% of the patients had HOXA9 modifications and 6% had CDX2 modifications.
HLX was down regulated in 10% of patients and amplified or upregulated in 17%.
Only a few patient samples contained expression changes in two of these genes,
implicating MIXL1 expression may be a marker of a subgroup of AML cases
distinct from HOXA9 and CDX2 expressing AMLs.
To determine if MIXL1, HOXA9, and CDX2 characterize distinct
subgroups, I analyzed the genes for mutual exclusivity between the patient
samples (Figure 22). While MIXL1 and HOXA9 had a tendency for mutual
exclusivity, CDX2 had no strong association with either of the two homeoboxes.
HLX had a tendency to be mutually exclusive with HOXA9, but had a minor
tendency to co-occur with MIXL1 or CDX2.
I also performed the same mutual exclusivity analysis with NF-κB pathway
members c-REL, BCL2, BCL2L1, and BCL2A1. While both MIXL1 and CDX2
had a tendency for co-occurrence with c-REL, MIXL1 had a stronger tendency to
co-occur with BCL2L1, while CDX2 had a stronger tendency to co-occur with
BCL2.
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Figure 21. MIXL1 overexpression marks a set of AML cases distinct from
those expressing CDX2, HLX or HOXA9. The TCGA AML patient dataset was
queried through the cBIOPortal database for >2 fold expression alterations as
determined by RNA-Seq, amplifications, or homozygous deletions, across 166
AML patient cases.

Each column represents a patient. MIXL1 is amplified or

up-regulated in 13% of the total AML cases.
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Figure 22. MIXL1 expression co-occurs with REL and BCL2L1 expression,
but not with HOXA9. A mutual exclusivity analysis from cBioPortal using the
TCGA AML database as depicted in Figure 21. Expression of MIXL1 has a
tendency to co-occur alongside expression of REL and BCL2L1, while
expression and modification in HOXA9 tend to be excluded from cell lines
expressing MIXL1 or BCL2L1.
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I next analyzed TCGA AML patient sample dataset for genes with any of
the commonly identified somatic mutations (NPM1, FLT3, DNMT3A, TET2 and
TP53) to determine with which mutations MIXL1 co-occurred or co-operated with
(Figure 23). The most common alteration was mutations in TP53 seen in 8
cases (38%) of MIXL1+ cases. Interestingly, this constitutes 66% of all the cases
with TP53 mutations (n=12) in the TCGA population. All of the other recurrent
mutations were also seen, but less frequently. Four patients had mutations in
NPM1; there were three cases each for DNMT3A and TET2. Two patients had
mutations in FLT3.
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Figure 23. High MIXL1 expression patient samples contain previously
identified somatic mutations of AML. 76% (16/21 cases) of high MIXL1
patients in the TCGA AML patient dataset contained previously identified
common somatic mutations for AML (NPM1, FLT3, DNMT3A, FLT, JAK3 and
TP53). The TCGA AML patient dataset was queried through the cBIOPortal
database for >2 fold expression alterations, mutations, amplifications, or
homozygous deletions, across 166 AML patient cases. Each column represents
a patient.
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Chapter 4. Discussion
In this study I have identified a BMP4-MIXL1-c-REL pathway which may
have an important role in normal hematopoietic development (Figure 24).
Mix.1 is induced in Xenopus embryos by BMP4 or Activin A in a SMAD5
dependent manner (17) although MIXL1 can be induced by TGF-β in human
hepatocellular carcinoma (54) and TGF-β and activin mouse ES cells (55) .
TGF-β from the glial cells within the bone marrow niche is thought to maintain
HSC quiescence (56)

In humans, BMP2, BMP4 and BMP7 regulate

maintenance, proliferation and repopulating activities of progenitors (57-59). Our
studies demonstrate for the first time that MIXL1 induction in human HSPCs by
BMP4. At present the distinction between the growth inhibitory versus mitogenic
response to TGF-β family ligands is dependent on biological assays.

MIXL1

expression may be a new marker that correlates with a pro-growth/ survival
response.

1. MIXL1 is over-expressed in a subset of AML
Analysis of the TCGA AML patient sample set identified a potentially
unique subset of high MIXL1 expressing cancers making up 13% of the cancer
set, a group both distinct and larger than the CDX2 and HOXA9 subtype. A
distinct aspect of the MIXL1 expressing cancer set is the prevalence of patients
with mutated p53: 38% of high-MIXL1 patients had p53 mutations and 67% of
patients with p53 mutations had high expression of MIXL1. p53 mutations are
associated with a strong resistance to chemotherapy (60); if MIXL1 expression is
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Figure 24. Proposed BMP/MIXL1/REL pathway. BMP4 binds to the complex
between BMP type 2 receptor (BMPR2 or AVCR2A) and BMP type 1 receptor
kinase (ALK2, ALK3, or ALK6).

In response to activation, the kinase

phosphorylates SMAD1 or SMAD5 which complexes with SMAD4 to activate the
transcription of MIXL1.

MIXL1 complexes with MZF1 and activates the

transcription of c-REL. C-REL in turn activates the transcription of BCL2 family
members.
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prevalent in the p53 mutant subset of AML, then it may identify a new potential
avenue to treat these untreatable patients.
While this implicates MIXL1 expression as a potentially strong diagnostic
marker in leukemia, it will be important to show that this can be replicated in a
much larger set of patients. The TCGA dataset contains complete patient data
for 166 patients of diverse types of AML; however this may not be an accurate
representation of the distribution of total AML cases.

In addition, the more

patient information gathered for further analysis, the more reliable and
statistically significant any correlations determined will be.
A number of technical reasons preclude MIXL1 detection in array based
global expression profiling studies. In addition to weak probes, the long 3’ UTR
includes Alu elements which can result in quenched signals. Thus availability of
the RNA-Seq data for the TCGA patients provided a valuable resource to
establish the importance of MIXL1.

2. MIXL1-positive AML lines are sensitive to LDN-193189
Expression of MIXL1 appears to identify a distinct subset of AML, which is
of interest if MIXL1 expression also identified a potential therapeutic target. It
would be quite relevant, then if the difference in sensitivity to kinase inhibitor
LDN-193189 seen between MIXL1-expressing lines and non-expressing lines is
also identified in patient samples. The differential cytotoxicity to 3 µM LDN193189, and growth suppression specific to those lines in lower expression

82

levels, implies that this defined subtype of AML may be responsive to Type 1
BMP receptor kinase suppression.
In the experiments presented, I treated a variety of leukemic lines with
LDN-193189 at concentrations up to 3 μM. While there was a distinct difference
between how MIXL1-expressing and non-expressing lines responded below this
concentration, any concentration at or above 4 μM was lethal to all cell lines
tested.

One possible explanation for this is that activation of the BMP pathway

may still be critical to the survival of U937 and HL60, yet this pathway does not
include MIXL1 activation in these cell lines.

Indeed, the BMP intermediate

SMAD1 has a different set of targets between U937 and K562 when induced by
BMP4 (61). In particular, my survey of their datasets identified that SMAD1 binds
to a unique peak in the MIXL1 locus in K562 but not U937.
Another likely explanation above 4 μM for LDN-193189 are lethal to U937
and HL60 despite the lack of MIXL1 activation is that LDN-193189 may be
inhibiting other kinases critical to the survival of these lines.

LDN-193189

functions in BMP signaling suppression by acting as an ATP-antagonist in the
BMP/Activin-regulated kinases ALK2/3/6 (ACVR1, BMPR1A, and BMPR1B)(62),
but it can function as an ATP-antagonist in other kinases, including ABL, VEGFR, YES1, and CAMKK2 (63), many of which have nearly as high sensitivity to
the inhibitor as the BMP pathway kinases. It would therefore be likely that even
cells not reliant on BMP pathway for survival would have some level of sensitivity
to the inhibitor.
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Since LDN-193189 can inhibit a large number of kinases beyond the
BMP-regulated kinases, it is possible that the sensitivity seen in cell lines with
high MIXL1 expression is either due to a combination of BMP-regulated kinase
inhibition and off-target, or off-target effects entirely. While I have shown that in
CD34+ hematopoietic precursor cells, MIXL1 can be activated by BMP4, I have
yet to show that blocking this pathway is critical to the survival of the MIXL1expressing cell lines.

Additionally, even within the BMP-regulated kinases

ALK2/3/6 (ACVR1, BMPR1A, and BMPR1B), I have yet to distinguish what role
each has and which is most important as a target of LDN-193189 in each cell
line. To better identify what role each potential target of LDN-193189 is playing
in the overall survival of these cell lines, I propose inhibiting each relevant kinase
through another means, specifically shRNA knockdown, and testing for both
expression changes in the downstream pathways and changes in growth and
survival of the cells.
While LDN-193189 targets a large number of kinases beyond the BMPregulated kinases, this may not preclude its use in therapeutics. Indeed, many of
the other kinase targets, including ABL1 and VEG-FR, are implicated in cancer
and are either currently targeted by therapeutics or considered likely targets for
therapeutics in the future. LDN-193189 has been already used in rodent models
of hepcidin induced chronic anemia (64) and fibrodysplasia ossificans
progressiva with constitutive activation of ACVR1 (65), and the side effects
exhibited from drug treatment were minimal. LDN-193189 may have significant
potential as a generally safe and therapeutic treatment for AML.
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3. Transcriptional regulation by MIXL1 in hematopoietic cells
I identified several important transcriptional targets of MIXL1 in this study.
While I have focused on c-REL, other critical genes identified by the ChIP-Seq
study may play a significant role in the leukemogenic activities of MIXL1. Future
research will better characterize other downstream targets and elucidate which
ones are responsible for the function of MIXL1.
The expected motif for MIXL1 binding is two TAATTGAATTA. This motif
was originally identified Gsc (goosecoid) promoter and was confirmed by SELEX
and reporter assays in ES cells and fibroblasts in vitro SELEX screens (66). The
expected motif, however, was less abundant in the targeted sequences identified
by ChIP-Seq than in randomized sequences.

Indeed, while the homeobox

binding motif is prevalent in AT-rich regions, CG-rich were very abundant in our
sequences identified by ChIP-Seq. This is of stark contrast to an analysis of
Mixl1 targets in mouse embryonic stem cells which had found the homeobox
binding motif to be considerably enriched (10).
Several possible reasons underlie the lack of this established DNA binding
motif in our target peaks. One possibility is that the MIXL1 is binding directly to
DNA in a way never previously characterized, which could be tested by purifying
the MIXL1 protein and testing the binding affinity with different DNA sequences.
A more likely explanation is that MIXL1 requires interactions with other proteins
to bind to DNA in this sequence. This is supported by the abundance of other
characterized transcription factor binding motifs in the peak regions and the
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length of the c-REL promoter segment required for MIXL1 regulation, which
implies a larger multiprotein complex is necessary.

While MIXL1 has been

shown previously to interact with other homeobox-containing proteins, it has also
been shown to interact with NEUROD1 (12), which does not contain a homeobox
domain, in a high throughput two-hybrid screen. As the most prevalent binding
motifs identified in the ChIP-Seq were zinc finger motifs, and MZF1 motifs were
prevalent in the c-REL promoter peak, MZF1 was a potential putative binding
partner.
MZF1 (myeloid zinc finger 1) is a zinc finger transcription factor associated
with the myeloid lineage (67, 68)

Expression of MZF1 inhibits apoptosis and

differentiation in myeloid leukemia cells (51, 52) and induces proliferation,
migration, invasion, and metastasis in colorectal cancer, cervical cancer, and
breast cancer (69-71).
Interactions between zinc fingers and homeobox proteins have been
identified previously. In breast cancer, an isoform of distal-less homeobox DLX4
binds to the zinc finger BRCA1 (72). In hematopoietic cells, zinc finger PML
binds to the homeobox HHEX (73). Additionally, a multitude of other potential
interactions between homeoboxes and zinc fingers have been identified through
two-hybrid assays (12).
Recent studies suggest that Mixl1 can interact with T box factors T,
Eomes, Tbx6 and Tbx20 directly to form protein complexes which function as
transcriptional repressors (74) . Additionally, in a high throughput mammalian
two hybrid screen, an interaction between TBX20 and MZF1 was identified (12).
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MIXL1, TBX20, and MZF1 may bind to targets as a multiprotein complex during
hematopoiesis, similar to the multiprotein complex between paired-type
homeobox protein NKX2-5, T box protein TBX3, and zinc finger protein GATA4 in
cardiac development (75).
To better identify how MIXL1 is interacting with these gene loci, we would
need to determine what the subunit composition of the MIXL1-containing
complexes are. I would need to repeat co-immunoprecipitation and luciferase
assay on each combination of potential complex members.

Next, I would want

to over-express each potential member in every combination to see which
combinations best activate the transcriptional targets. Finally, I would knock out
each member from an expressing AML line to determine the minimal complex
necessary for transcriptional activation.

4. c-REL is a transcriptional target of MIXL1
c-REL is a promising target for MIXL1 transcriptional activation due to its
strong sequence similarity to the established viral oncogene v-REL and
established role in the activation of anti-apoptotic genes BCL2L1 and BCL2A1
(76). Amplification and overexpression of c-REL is implicated in diffuse large B
cell lymphoma (38). c-REL overexpression is seen in a wide array of other
cancer types, including colorectal cancer (77), breast cancer (78), lung
carcinoma (79), squamous cell carcinoma (80, 81), retinoblastoma (82),
endometrial carcinoma (83), and pancreatic cancers (84).
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Activity of the NF-κB DNA binding factors comprising of 5 proteins which
heterodimerize to bind DNA, is regulated both at the transcriptional and posttranscriptional level. Cytoplasmic sequestration of the five proteins by inhibitors
NFKBIA, B and E regulates their activity post-transcriptionally (85). Expression
profiling suggests down regulation of all the NFKBI members and preferential
upregulation of c-REL, RELB and NFKB2.

Furthermore, recent evidence

suggests potential functional differences in the activity depending upon the
subunit composition. Thus c-REL homodimers or heterodimer with NFKB2 or
RELB may have varied responses (37, 86).

Notably, there is an absolute

requirement for c-REL in B lymphoid development (87), though the factors
surrounding both the regulation of c-REL and the downstream effects distinct
from the other family members is currently unknown.

Overall, this would

implicate that MIXL1 and c-REL may activate preferentially a “non-canonical” NFκB pathway distinct from the one regulated by the RELA/NFKB1 complex.

5. Summary
In summation, we have identified MIXL1 to mark a new subset of AML and
c-REL as a direct transcriptional target of MIXL1. Targeting the BMP receptor
upstream of MIXL1 may be a novel therapeutic avenue to explore in AML.
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Appendix: Peaks identified by all analyses of the MIXL-overexpression
ChIP-Seq dataset. The following set of peaks was generated by normalizing to
the two control samples in three combinations and then finding the overlapping
set (as visualized in Figure 5): Flag-1MIXL to IgG-Control and Flag-Control, Flag2MIXL to IgG-Control and Flag-Control, and Flag-1MIXL and Flag-2MIXL
combined to IgG-Control and Flag-Control. A total of 179 peaks were identified in
this stringent set. This table was generated as part of the analysis performed by
Dr. Yue Lu and Dr. Shoudan Liang for ChIP-seq. Columns are as followed:
Site position:

The location of the peak on Human genome assembly

Hg18/NCBI36.
Gene name: Gene loci within 25 kb of the peak.
Location: Relative location of the peak to the nearest gene loci. Designations
are:

Upstream – 5 to 25 kb upstream of the transcription start site (TSS),

Promoter – 0 kb to 5 kb upstream of the TSS, Body – Between the TSS and
transcription sequence end (TSE), TSE – 0 to 5 kb downstream of the
transcription sequence end, Downstream – 5 to 25 kb downstream of the TSE.
Unlabelled have no nearby loci.
Fold enrichment: Fold enrichment of the peak region in experimental sets over
control sets.
Number of Tags: The number of sequence tags that contributed to this peak.
-10Log (pvalue): Negative Log base ten of the p-value for each peak.
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site_position
chr1:100370463-100371655
chr1:1082711-1084387
chr1:153411692-153412694
chr1:153480474-153481740
chr1:154452528-154453384
chr1:154986531-154989082
chr1:167341593-167342441
chr1:178117582-178119503
chr1:221054670-221055313
chr1:230832149-230833445
chr1:234753905-234754746
chr1:39228761-39230181
chr1:8799585-8800833
chr1:9473155-9473998
chr1:9609526-9610602
chr1:9633942-9634866
chr10:121291414-121293247
chr10:124757753-124759210
chr10:38731545-38732467
chr10:43163960-43164521
chr10:70937383-70938053
chr10:76639460-76641469
chr10:88126705-88127529
chr10:93547695-93548906
chr10:98469350-98471263
chr11:119886935-119887385
chr11:127547489-127547696
chr11:18753771-18754240
chr11:2405808-2406392
chr11:34029256-34031806
chr11:47385814-47387193
TSE
promoter
promoter
promoter

body
upstream
promoter
promoter

TSPAN15
VDAC2
TNKS2
PIK3AP1

PTPN5
TRPM5
CAPRIN1
SLC39A13

promoter
promoter
promoter

LGALS8
AKIRIN1
RERE

promoter
promoter
promoter
promoter

promoter
promoter
downstream
promoter
promoter
promoter

KRTCAP2,TRIM46
GBA
SLC25A44
HDGF
ATP1B1
TOR1AIP1

PIK3CD
RGS10
IKZF5,ACADSB
CDC10L

Location
promoter

gene_name
SASS6,CCDC76

Fold
Number
-10LOG
enrichment of tags
(pvalue)
5.45
70
67.94
6.72
132
139.37
7.65
63
85.3
4.55
88
62.49
3.99
296
151.79
6.32
124
66.28
7.31
48
124.79
6.01
147
130.37
8.93
27
107.73
7.72
62
146.53
6.83
35
86.28
7.52
72
69.02
7.29
66
119.64
8.65
56
121.24
10.55
79
142.8
5.73
60
78.06
5.2
85
101.97
7.4
82
105.68
9.58
29
92.31
10.25
38
108.47
7.21
47
95.72
4.83
98
114.52
12.11
39
106.9
10.42
60
148.58
6.66
94
101.59
7.25
25
69.29
16.58
14
134.56
16.01
17
90.98
10.64
25
96.64
5.15
95
66.1
6.87
62
73.23

91

chr11:508367-509334
chr11:61203893-61204533
chr11:68275215-68275961
chr11:72031487-72032468
chr11:9342002-9343005
chr12:118589619-118590562
chr12:120131529-120133303
chr12:1641108-1641700
chr12:47030102-47031632
chr12:95824895-95826039
chr13:105985735-105987133
chr13:110364326-110366473
chr13:43351097-43352595
chr14:106145545-106145909
chr14:73026948-73028277
chr14:99821115-99822235
chr15:29070366-29072007
chr15:43666309-43667700
chr15:49701409-49702967
chr15:54966333-54967442
chr15:62466763-62467498
chr15:65963711-65964610
chr15:68527000-68528404
chr16:31098123-31099856
chr16:46835533-46835976
chr16:51721377-51722741
chr16:657758-658373
chr16:66463257-66465299
chr16:84635253-84635864
chr16:87760902-87761906
chr16:88520016-88520674
chr17:12861450-12862503
chr17:30502035-30502785
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
downstream
promoter
promoter
promoter
body
promoter

promoter
promoter
body
promoter
promoter
upstream
body
promoter
body

DAGLA
MTL5
PDE2A
PRKAB1
P2RX4
ZNF641
NEDD1
EFNB2
ANKRD10
CCDC122,C13orf31
C14orf169
SLC25A29
MTMR10
PLDN
DMXL2
LOC145783
TRIP4

FUS
LONP2
CHD9
RHOT2
EDC4
CDH15
TUBB3
ELAC2
UNC45B

9.8
11.68
10.4
7.23
5.43
10.26
8.93
13.53
6.02
9.95
9.57
5.43
10.71
21.1
7.75
8.16
4.86
8.14
5.54
7.65
9.47
6.09
7.28
5.65
8.69
6.03
10.06
6.83
7.14
9.04
7.27
11.24
5.44

36
29
46
43
45
73
104
26
70
56
77
160
57
15
52
49
75
67
77
69
69
47
78
144
35
63
32
83
27
47
27
48
164

105.14
98.56
140.55
86.01
50.47
227.01
167.49
91.56
116.6
129.28
139.2
153.79
122.33
107.01
77.86
113.68
82.69
145.19
125.52
157.56
202.42
77.71
120.21
154.83
91.66
116.02
95.45
51.42
83.17
90.41
64.71
152.38
98.23
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chr17:37097849-37099490
chr17:39543640-39544659
chr17:41626353-41627609
chr17:53282123-53283069
chr17:7124493-7125013
chr18:148098-149269
chr18:58341020-58341483
chr18:9092283-9093337
chr19:10666975-10667833
chr19:14377476-14378551
chr19:2770179-2771331
chr19:4320061-4321948
chr19:55182096-55182785
chr19:60363117-60364407
chr19:63422082-63422569
chr19:8551405-8552171
chr2:109029691-109030422
chr2:144805719-144807166
chr2:183288716-183289819
chr2:208197446-208199695
chr2:218328982-218329926
chr2:231284904-231286412
chr2:240613319-240614157
chr2:39517179-39518454
chr2:60961441-60962652
chr2:64568721-64569193
chr2:85696451-85697304
chr2:86495597-86495902
chr2:96294363-96296376
chr20:1046903-1047656
chr20:18066017-18066962
chr20:26136641-26137576
chr20:29663539-29664931
upstream
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter

GTDC1
DNAJC10
FAM119A
DIRC3
CAB39
NDUFA10
MAP4K3
REL
USP39
TMEM127,CIAO1
PSMF1
CSRP2BP

promoter
promoter
promoter
promoter
promoter
downstream
downstream
promoter
body
body
upstream

MRPS23
SLC2A4
USP14
ZCCHC2
NDUFV2
ILF3
DDX39
ZNF554
SH3GL1
VRK3
TNNI3
MYO1F

promoter
body

EIF1
HDAC5

7.55
5.29
5.79
10.49
8.31
5.85
11.9
7.67
7.26
5.47
10.66
6.73
8.54
10.66
15.31
12.34
6.93
6.17
11.73
4.52
11.05
6.16
12.65
6.32
9.79
11.9
9.09
14.88
5.78
11.15
5.92
4.51
8.15

92
61
90
66
36
70
22
82
53
57
56
91
56
47
18
59
27
61
56
138
30
81
35
73
73
22
58
23
104
39
49
171
177

156.7
75.92
148.39
159.6
82
98.42
104.59
124.29
100.56
105.59
98.46
81.82
112.82
94.92
99.28
155
52.19
62.76
154.25
104.45
91.93
58.89
117.06
83.87
142.2
87.09
136.51
128.97
77.6
97.43
100.85
163.46
100.29

93

chr20:30019791-30020960
chr20:34005247-34006579
chr20:43424790-43425893
chr20:43995718-43997880
chr20:6051064-6051910
chr21:45183817-45185018
chr21:46166957-46168073
chr22:30215674-30216941
chr22:44890951-44891648
chr3:129881882-129883049
chr3:132704139-132704713
chr3:143779916-143780809
chr3:157874292-157875969
chr3:158288967-158290241
chr3:158439581-158439957
chr3:159844820-159845455
chr3:180271815-180273139
chr3:40325257-40326747
chr3:49951972-49953275
chr3:53081401-53082439
chr3:88189857-88191895
chr3:9412642-9414529
chr4:140436020-140436664
chr4:144653627-144655034
chr4:15265187-15267009
chr4:172011274-172011568
chr4:185186291-185187153
chr4:186629373-186629928
chr4:2506433-2508320
chr4:40910100-40911927
chr4:41631637-41632502
chr4:6627106-6629004
chr4:6990416-6991886
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter

promoter
promoter
promoter
promoter
body

CGGBP1
SETD5
NDUFC1
SMARCA5
FBXL5

CCDC110
APBB2
TMEM33
MAN2B2
TBC1D14

promoter
promoter
promoter

MRPL3
ATR
TIPARP

GFM1
ZMAT3
EIF1B
RBM6

promoter
promoter
promoter
promoter
promoter
promoter
body
promoter
downstream

XKR7
SCAND1
SYS1
PCIF1
FERMT1
C21orf67
PCBP3
EIF4ENIF1
LOC400931

12.96
7.11
5.37
6.94
7.11
9.57
12.34
5.83
10.99
6.69
9.47
6.92
6.04
8.12
16.58
11.03
6.46
7.23
5.67
11.9
7.58
4.53
14.1
4.74
7.4
27.78
9.53
9.65
4.89
5.15
6.3
6.01
6.04

156
86
65
101
26
75
40
66
36
76
27
53
109
77
15
46
61
89
88
64
109
161
51
83
94
15
41
19
133
76
53
86
86

173.76
145.41
111.67
110.54
73.6
94.97
100.56
112.48
115.41
123.03
101.08
125.46
152.82
150.42
85.54
182.96
116.69
93.84
195.31
143.45
149.87
164.66
205.52
79.27
126.9
133.58
148.02
78.06
140.79
74.24
99.03
83.36
110.19
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chr6:88467636-88469003
chr7:105581441-105581841
chr7:116289481-116290748
chr7:1480097-1480815
chr7:4889432-4890279
chr7:5402506-5404226
chr7:55400456-55401923
chr7:6278588-6279343
chr7:65783909-65785122
chr7:75461351-75462413
chr7:75905120-75905486

chr6:86444545-86445994

chr4:77287964-77289097
chr4:84595427-84596455
chr5:126140153-126142456
chr5:131853280-131855024
chr5:134268021-134269311
chr5:139906921-139908326
chr5:150807080-150808183
chr5:171546448-171548631
chr5:36341637-36341890
chr5:36911650-36913606
chr5:43027710-43029352
chr5:74842885-74843826
chr6:10909536-10909757
chr6:109910129-109911249
chr6:114397754-114399542
chr6:137155129-137156222
chr6:142509768-142510478
chr6:163754408-163755513
chr6:41861658-41863865
promoter
body
promoter
promoter
promoter
promoter
promoter
promoter

promoter
promoter
body
promoter
body
promoter
promoter
TSE
promoter
body

COL4A3BP,POLK
MAK
ZBTB24
HDAC2
MAP3K5
VTA1
QKI
TOMM6
SNHG5,SNORD50A,
SNORD50B
AKIRIN2,NCRNA001
20
CAPZA2
INTS1
RADIL
TNRC18
LANCL2
CYTH3
LOC100289135
TMEM120A
ZP3

promoter

promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
upstream
promoter

NUP54
HELQ,MRPS18C
LMNB1
IRF1
PCBD2
EIF4EBP3
SLC36A1
STK10
RANBP3L
NIPBL

7.83
12
6.3
12.83
10.44
6.13
5.96
6.94
6.92
7.31
20.74

7.66

10.39
9.17
5.04
5.69
11.9
5.49
9.41
5.81
20.13
4.74
4.36
6.19
20.83
5.6
6.49
7.09
11.58
6.14
6.46

90
20
66
39
36
119
74
47
65
44
21

109

98
76
162
99
98
89
62
145
17
103
105
51
14
41
95
84
49
37
132

175.61
78.09
82.89
132.6
92.26
130.6
103.72
98.07
120.47
74.47
141.62

197.73

284.03
156.45
145.67
103.51
219.06
131.77
111.54
133.58
134.56
106.91
90.45
99.08
140.47
56.78
137.56
178.43
136.13
69.47
96.4
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chr7:87342930-87344460
chr7:99516745-99517741
chr7:99904614-99905602
chr8:142795117-142795846
chr8:144983269-144984286
chr8:146589-147330
chr8:27187763-27188526
chr8:28535547-28536566
chr8:90983090-90984625
chr8:91726570-91728158
chr9:114134880-114136159
chr9:133367851-133368844
chr9:138804959-138806804
chr9:139632021-139633388
chr9:36125703-36127420
chrX:153371303-153372803
chrX:69426163-69427181

promoter
promoter
upstream
promoter
downstream

promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter
promoter

SLC25A40,DBF4
ZNF3
LOC402573
PUF60
RPL23AP53

OSGIN2
TMEM64
ROD1
POMT1
TMEM141
C9orf37,EHMT1
GLIPR2
SLC10A3
PDZD11,KIF4A

8.38
10.31
9.97
15.31
7.08
7.02
8.67
8.05
7.27
5.76
5.79
6.34
6.13
5.73
4.73
7.63
9.34

79
87
51
30
78
39
44
57
68
78
48
38
88
56
65
74
53

130.92
208.49
111.46
104.36
170.73
97.43
94.3
131.34
115.28
129.92
89.5
89.75
131.77
85.15
84.86
104.54
164.21
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